Evaluation of the Performance of BCG with Synthetic Nano Selenium as a Booster in the Formulation of a Vaccine Candidate Against Staphylococcus Aureus Based on Isde in a Mouse Model

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Microbiology, TeMS.C., Islamic Azad University, Tehran, Iran

2 Associate Professor, Department of Microbiology, TeMS.C., Islamic Azad University, Tehran, Iran

3 Associate Professor, Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Assistant Professor, R&D Department, Research & Production Complex, Pasteur Institute of Iran, Tehran

10.48305/jims.v43.i831.1151

Abstract

Background: Staphylococcus aureus causes various hospital-acquired infections and contributes to increased mortality. Vaccination is an effective method to combat these infections. Iron plays an essential role in bacterial pathogenesis. The IsdE protein, an iron (heme) transporter, is a promising vaccine development candidate. This study investigates the effect of BCG performance along with synthetic nano selenium as a booster in formulating a candidate vaccine against Staphylococcus aureus based on IsdE protein and the role of MF59 adjuvant.
Methods: After expressing the IsdE protein using IPTG, a one-millimolar nickel column was used for purification. The vaccine formulation, incorporating the adjuvants MF59, BCG, and synthetic nano-selenium, was prepared and administered subcutaneously in three doses, with two-week intervals, to five groups of Balb/C mice. The levels of total IgG and IgG1 and IgG2a isotypes were measured using ELISA. The mice were challenged with a bacterial dose of 5 × 108 CFU. The bacterial load in internal organs was counted, and animal survival was monitored for 30 days.
Findings: Total IgG and the IgG1 and IgG2a isotypes showed a significant increase in all groups receiving the vaccine candidate compared to the control group. The bacterial load in internal organs (liver, kidneys, and spleen) and the mortality rate in the IsdE+MF59+BCG+Nano-selenium group were significantly reduced compared to the other immunized and control groups.
Conclusion: The results demonstrated that the adjuvant MF59, BCG, and synthetic nano-selenium boosters enhance humoral immunity against Staphylococcus aureus infection.

Highlights

Fatemeh Khosravani Pour: Google Scholar

Setareh Haghighat: Google Scholar

Mohammad Hossein Yazdi: Google Scholar

Seyed Mehdi Hassanzadeh: Google Scholar

Keywords

Main Subjects

References

  1. Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence 2021; 12(1): 547-69.
  2. Jenul C, Horswill AR. Regulation of Staphylococcus aureus virulence. Microbiol Spectr 2019;7(2):10.1128/microbiolspec. gpp3-0031-2018.
  3. Zapotoczna M, Heilbronner S, Speziale P, Foster TJ. Iron-regulated surface determinant (Isd) proteins of Staphylococcus lugdunensis. J Bacteriol 2012; 194(23): 6453-67.
  4. Vahdani Y, Faraji N, Haghighat S, Yazdi MH, Mahdavi M. Molecular cloning and immunogenicity evaluation of IsdE protein of methicillin resistant Staphylococcus aureus as vaccine candidates. Microb Pathog 2021; 157: 104953.
  5. Grigg JC, Vermeiren CL, Heinrichs DE, Murphy ME. Heme coordination by Staphylococcus aureus IsdE. J Biol Chem 2007; 282(39): 28815-22.
  6. Fowler Jr VG, Proctor RA. Where does a S taphylococcus aureus vaccine stand? Clin Microbiol Infect 2014; 20 Suppl 5(0 5): 66-75.
  7. Rojo-Montejo S, Collantes-Fernández E, Regidor-Cerrillo J, Rodríguez-Bertos A, Prenafeta A, Gomez-Bautista M, et al. Influence of adjuvant and antigen dose on protection induced by an inactivated whole vaccine against Neospora caninum infection in mice. Vet Parasitol 2011; 175(3-4): 220-9.
  8. Singh M, O'Hagan D. Advances in vaccine adjuvants. Front Immunol 1999; 17(11): 1075-81.
  9. O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013; 12(1): 13-30.
  10. Ko E-J, Kang S-M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother 2018; 14(12): 3041-5.
  11. Cable J, Srikantiah P, Crowe Jr JE, Pulendran B, Hill A, Ginsberg A, et al. Vaccine innovations for emerging infectious diseases—a symposium report. Ann N Y Acad Sci 2020; 1462(1): 14-26.
  12. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168(2): 919-25.
  13. Franco AR, Peri F. Developing new anti-tuberculosis vaccines: focus on adjuvants. Cells. 2021;10(1):78.
  14. Marques Neto LM, Kipnis A, Junqueira-Kipnis AP. Role of metallic nanoparticles in vaccinology: implications for infectious disease vaccine development. Front Immunol 2017; 8: 239.
  15. Yazdi MH, Mahdavi M, Varastehmoradi B, Faramarzi MA, Shahverdi AR. The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study. Biol Trace Elem Res 2012; 149(1): 22-8.
  16. Ananth A, Keerthika V, Rajan MR. Synthesis and characterization of nano-selenium and its antibacterial response on some important human pathogens. Current Science 2019; 116(2): 285-90.
  17. Ranjbariyan A, Haghighat S, Yazdi MH, Arbabi Bidgoli S. Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus. World J Microbiol Biotechnol 2023; 39(1): 16.
  18. Modrzejewska-Sikorska A, Konował E, Klapiszewski Ł, Nowaczyk G, Jurga S, Jesionowski T, et al. Lignosulfonate-stabilized selenium nanoparticles and their deposition on spherical silica. Int J Biol Macromol 2017; 103: 403-8.
  19. Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine 2018; 36(40): 6007-16.
  20. Delfani S, Mohabati Mobarez A, Imani Fooladi AA, Amani J, Emaneini M. Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA–IsdB–Hlg as a vaccine candidate. Med Microbiol Immunol 2016; 205: 47-55.
  21. Bagherzadeh M, Haghighat S, Mahdavi M. Evaluation of humoral and cellular immunity of recombinant autolysin protein Staphylococcus aureus in mouse model [in Persian]. Medical Science Journal of Islamic Azad University 2021; 31(2): 147-55.
  22. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105(30): 10501-6.
  23. Han H-W, Patel KD, Kwak J-H, Jun S-K, Jang T-S, Lee S-H, et al. Selenium nanoparticles as candidates for antibacterial substitutes and supplements against multidrug-resistant bacteria. Biomolecules 2021; 11(7): 1028.
  24. Mavandadnejad F, Yazdi MH, Hassanzadeh SM, Mahdavi M, Faramarzi MA, Pazoki‐Toroudi H, et al. Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study. IET Nanobiotechnol 2018; 12(1): 57-63.
  25. Mohammadi Y. Evaluation of the immunogenicity and efficacy of a chimeric OMP25–OMP31 antigen in BALB/c mice. Vet Med Sci 2021; 7(5): 2008-14.
  26. Paydarnia N, Mansoori B, Esmaeili D, Kazemi T, Aghapour M, Hajiasgharzadeh K, et al. Helicobacter pylori recombinant CagA regulates Th1/Th2 balance in a BALB/c murine model. Adv Pharm Bull 2020; 10(2): 264-70.
  27. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005; 12(3): 387-98.
  28. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun 1977; 16(1): 249-57.
  29. Dos Santos D, Muniz I, Queiroz A, Pereira I, Souza M, Lima L, et al. Individual variation is the key to the development of a vaccine against S taphylococcus aureus: a comparative study between mice lineages. Braz J Med Biol Res 2018; 51(5): e6773.
Journal of Isfahan Medical School
Volume 43, Issue 831
3rd Week November
November and December 2025
Pages 1151-1163

Files

History

  • Receive Date: 01 February 2025
  • Accept Date: 13 September 2025

Share

How to cite

Statistics